PART I Overview We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics. We are advancing a pipeline that includes three cl...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-088172 | EDGAR | 90K words |
| 2025-03-19 | 2024-12-31 | 0001558370-25-003302 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001558370-24-004247 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0001558370-23-003964 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001558370-22-004420 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001558370-21-003493 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269603 | EDGAR | 60K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104035 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007382 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015524 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001558370-24-011898 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008066 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018425 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014090 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0001558370-23-008194 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017574 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0001558370-22-012344 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001558370-22-008432 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-03 | 0001193125-26-088141 | EDGAR | 2K words |
| 2025-12-17 | 0001193125-25-322877 | EDGAR | — |
| 2025-12-15 | 0001193125-25-318429 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269538 | EDGAR | — |
| 2025-08-06 | 0000950170-25-104015 | EDGAR | — |
| 2025-06-11 | 0001104659-25-058523 | EDGAR | — |
| 2025-05-12 | 0001104659-25-047304 | EDGAR | — |
| 2025-03-19 | 0001104659-25-025558 | EDGAR | — |
| 2025-01-30 | 0001104659-25-007610 | EDGAR | — |
| 2025-01-29 | 0001104659-25-007198 | EDGAR | — |
121 total filings indexed. 93 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001472012 |
| Ticker | IMNM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.immunome.com |
| Listed | 2020-10-02 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report